Alexander Spira, MD, PhD, FACP, discusses the PAPILLON trial, including its methods, design, and rationale as well as new data from the study.
In a recent trial, researchers found that Xpovio plus chemo had activity in NSCLC patients with KRAS mutations other than ...
Datroway demonstrated durable antitumor activity and an acceptable safety profile in advanced NSCLC with actionable genomic ...
The most common form of lung cancer is primarily found in non-smokers, a new study reveals. Doctors react to the surprising ...
After realizing that a stronger support system would have helped me emotionally and spiritually in my cancer journey, I ...
Early diagnosis of lung cancer is a critical priority in clinical practice. It may help reduce the rate of ...
Early diagnosis of lung cancer is a critical priority in clinical practice. It may help reduce the rate of lung-cancer-related mortality, extend disease-free survival, and allow patients to live ...
Lung cancer cases are increasing in people who have never smoked, especially in women, a new study by the World Health ...
Multidrug resistance in cancer can be overcome by combining a drug that blocks a key enzyme with another anticancer drug, ...
The Phase III SERENA-6 trial is the first global trial to use a circulating tumor DNA-guided approach to detect endocrine ...
Ridgefield, Conn., U.S., and Ingelheim, GermanyZongertinib would be the first orally administered, targeted therapy for previously treated ...
"Bacterial and viral infections can also cause genetic mutations and chronic inflammation, which contribute to the development of cancer." In some cases, lung cancer can develop seemingly at ...